Smoothened Homolog (Protein Gx or SMO) - Pipeline Review, H1 2016

Published: Jun, 2016 | Pages: 78 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Smoothened Homolog (Protein Gx or SMO) - Pipeline Review, H1 2016

Summary

Global Markets Direct's, 'Smoothened Homolog (Protein Gx or SMO) - Pipeline Review, H1 2016', provides in depth analysis on Smoothened Homolog (Protein Gx or SMO) targeted pipeline therapeutics. 

The report provides comprehensive information on the Smoothened Homolog (Protein Gx or SMO), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Smoothened Homolog (Protein Gx or SMO) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Smoothened Homolog (Protein Gx or SMO)
- The report reviews Smoothened Homolog (Protein Gx or SMO) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in Smoothened Homolog (Protein Gx or SMO) targeted therapeutics and enlists all their major and minor projects 
- The report assesses Smoothened Homolog (Protein Gx or SMO) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news and deals related to Smoothened Homolog (Protein Gx or SMO) targeted therapeutics

Reasons To Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand the targeted therapy areas and indications for Smoothened Homolog (Protein Gx or SMO)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Smoothened Homolog (Protein Gx or SMO) development landscape 
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

 Table of Contents

Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Smoothened Homolog (Protein Gx or SMO) Overview 7
Therapeutics Development 8
Smoothened Homolog (Protein Gx or SMO) - Products under Development by Stage of Development 8
Smoothened Homolog (Protein Gx or SMO) - Products under Development by Therapy Area 9
Smoothened Homolog (Protein Gx or SMO) - Products under Development by Indication 10
Smoothened Homolog (Protein Gx or SMO) - Pipeline Products Glance 12
Late Stage Products 12
Early Stage Products 13
Smoothened Homolog (Protein Gx or SMO) - Products under Development by Companies 14
Smoothened Homolog (Protein Gx or SMO) - Products under Development by Universities/Institutes 17
Smoothened Homolog (Protein Gx or SMO) - Therapeutics Assessment 19
Assessment by Monotherapy/Combination Products 19
Assessment by Mechanism of Action 20
Assessment by Route of Administration 21
Assessment by Molecule Type 23
Smoothened Homolog (Protein Gx or SMO) - Companies Involved in Therapeutics Development 25
BeiGene, Ltd. 25
F. Hoffmann-La Roche Ltd. 26
Ignyta, Inc. 27
Mayne Pharma Group Limited 28
Novartis AG 29
PellePharm, Inc. 30
Pfizer Inc. 31
Redx Pharma Plc 32
Stemline Therapeutics, Inc. 33
Smoothened Homolog (Protein Gx or SMO) - Drug Profiles 34
glasdegib - Drug Profile 34
Product Description 34
Mechanism Of Action 34
R&D Progress 34
GSA-10 - Drug Profile 36
Product Description 36
Mechanism Of Action 36
R&D Progress 36
itraconazole - Drug Profile 37
Product Description 37
Mechanism Of Action 37
R&D Progress 37
LEQ-506 - Drug Profile 40
Product Description 40
Mechanism Of Action 40
R&D Progress 40
Monoclonal Antibody to Inhibit Smoothened for Oncology - Drug Profile 41
Product Description 41
Mechanism Of Action 41
R&D Progress 41
patidegib hydrochloride - Drug Profile 42
Product Description 42
Mechanism Of Action 42
R&D Progress 42
RDX-001 - Drug Profile 43
Product Description 43
Mechanism Of Action 43
R&D Progress 43
Small Molecules to Antagonize Smoothened (Smo) Receptor for Cancer - Drug Profile 44
Product Description 44
Mechanism Of Action 44
R&D Progress 44
Small Molecules to Inhibit Smoothened Homolog for Oncology - Drug Profile 45
Product Description 45
Mechanism Of Action 45
R&D Progress 45
sonidegib phosphate - Drug Profile 46
Product Description 46
Mechanism Of Action 46
R&D Progress 46
taladegib - Drug Profile 51
Product Description 51
Mechanism Of Action 51
R&D Progress 51
vismodegib - Drug Profile 53
Product Description 53
Mechanism Of Action 53
R&D Progress 53
Smoothened Homolog (Protein Gx or SMO) - Dormant Projects 59
Smoothened Homolog (Protein Gx or SMO) - Discontinued Products 63
Smoothened Homolog (Protein Gx or SMO) - Featured News & Press Releases 64
Jun 02, 2016: Curis Announces Presentations Related to Erivedge at 2016 ASCO Annual Meeting 64
Jun 02, 2016: FDA Grants Orphan Drug Designation to SUBA-Itraconazole for Treatment of Patients with BCCNS 64
Sep 29, 2015: HedgePath Pharmaceuticals Announces Commencement of Patient Treatment in its Phase II(b) Clinical Trial 65
Aug 21, 2015: HedgePath Pharmaceuticals Launches Clinical Trial for its Proposed Cancer Treatment 65
Aug 20, 2015: Novartis drug Odomzo gains EU approval for locally advanced basal cell carcinoma, providing new non-invasive therapy for patients 66
Jul 24, 2015: FDA approves Novartis drug Odomzo (sonidegib) for locally advanced basal cell carcinoma (laBCC), a form of skin cancer 68
May 20, 2015: Curis Announces Presentations of Erivedge Clinical Data at 2015 ASCO Annual Meeting 68
May 18, 2015: New Equity Investment In Hedgepath Pharmaceuticals Ahead Of Commencing Phase IIB Trial With Suba-Itraconazole In Skin Cancer 69
Mar 09, 2015: Skin tumors develop specific mutations to resist drug, researchers say 70
Mar 02, 2015: Basal Cell Carcinoma Drug Encourages Both Cancer Regression and Loss of Taste in Patients 72
Dec 16, 2014: HedgePath Pharmaceuticals Receives IND Clearance to Commence Development of its Proposed Cancer Treatment 73
Nov 18, 2014: HedgePath Pharmaceuticals Files IND Application 73
Sep 17, 2014: Novartis presents oncology research advances with new data on sonidegib at ESMO 2014 74
Jun 23, 2014: Curis Announces Investigational New Drug Application Filing by Roche to Initiate a Phase II Study of Erivedge (vismodegib) in Idiopathic Pulmonary Fibrosis 75
Jun 01, 2014: Pivotal data for Novartis' investigational compound LDE225 show marked tumor responses in advanced basal cell carcinoma 75
Appendix 77
Methodology 77
Coverage 77
Secondary Research 77
Primary Research 77
Expert Panel Validation 77
Contact Us 77
Disclaimer 78

List of Tables

Number of Products under Development for, H1 2016 8
Number of Products under Development by Therapy Area, H1 2016 9
Number of Products under Development by Indication, H1 2016 10
Comparative Analysis by Late Stage Development, H1 2016 12
Comparative Analysis by Early Stage Products, H1 2016 13
Number of Products under Development by Companies, H1 2016 14
Products under Development by Companies, H1 2016 15
Products under Development by Companies, H1 2016 (Contd..1) 16
Number of Products under Investigation by Universities/Institutes, H1 2016 17
Products under Investigation by Universities/Institutes, H1 2016 18
Assessment by Monotherapy/Combination Products, H1 2016 19
Number of Products by Stage and Mechanism of Action, H1 2016 20
Number of Products by Stage and Route of Administration, H1 2016 22
Number of Products by Stage and Molecule Type, H1 2016 24
Pipeline by BeiGene, Ltd., H1 2016 25
Pipeline by F. Hoffmann-La Roche Ltd., H1 2016 26
Pipeline by Ignyta, Inc., H1 2016 27
Pipeline by Mayne Pharma Group Limited, H1 2016 28
Pipeline by Novartis AG, H1 2016 29
Pipeline by PellePharm, Inc., H1 2016 30
Pipeline by Pfizer Inc., H1 2016 31
Pipeline by Redx Pharma Plc, H1 2016 32
Pipeline by Stemline Therapeutics, Inc., H1 2016 33
Dormant Projects, H1 2016 59
Dormant Projects (Contd..1), H1 2016 60
Dormant Projects (Contd..2), H1 2016 61
Dormant Projects (Contd..3), H1 2016 62
Discontinued Products, H1 2016 63